Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Lymphoid 1Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 505Urinary Bladder Neoplasms 139Carcinoma, Renal Cell 117Neoplasms 67Kidney Neoplasms 53Non-Muscle Invasive Bladder Neoplasms 43Neoplasm Metastasis 38Carcinoma, Transitional Cell 38Breast Neoplasms 30Testicular Neoplasms 28Recurrence 20Wilms Tumor 18Parkinson Disease 4, Autosomal Dominant Lewy Body 14Pain 13Ovarian Neoplasms 13Urologic Neoplasms 12Testicular Germ Cell Tumor 12Teratoma 12Seminoma 12Multiple Myeloma 12Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Carcinoma, Ovarian Epithelial 11Carcinoma 11Urogenital Neoplasms 10Neuroblastoma 10Lymphoma, Non-Hodgkin 10Lymphoma, Mantle-Cell 10Lymphoma, Large-Cell, Immunoblastic 10

Interventions

Pioglitazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Diabetes Mellitus, Type 2 × Genitourinary × Clear all
NCT05098327 2023-08-15

Pioglitazone and Insulin Resistance in ADT

State University of New York at Buffalo

Phase 3 Withdrawn
Genitourinary

Diabetes Mellitus, Type 2, Insulin Resistance, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡